Description
Imidapril is a new ACE inhibitor launched in Japan as a once-daily therapy for
hypertension. Its active metabolite has more potent inhibitory effects on all tissue ACES from
spontaneously hypertensive rats (SHRs) and Wistar Kyoto rats (WKYs) than many other ACE
inhibitors including enalapril and captopril. It has a very long duration of action. In strokeprone
spontaneously hypertensive rats (SHRSP), imidapril is effective in stroke prevention at
a considerably lower dose than enalapril. This stroke preventive effect has been suggested to
be primarily by an indirect mechanism related to the amelioration of kidney dysfunction.
Definition
ChEBI: Imidapril is a member of the class of imidazolidines that is (4S)-1-methyl-2-oxoimidazolidine-4-carboxylic acid in which the hydrogen of the imidazolidine nitrogen has been substituted by (1S)-1-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}ethyl group. It is the prodrug for imidaprilat, an ACE inhibitor used for the treatment of chronic heart failure. It has a role as an antihypertensive agent, an EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor and a prodrug. It is a dipeptide, a member of imidazolidines, a dicarboxylic acid monoester, a secondary amino compound, an ethyl ester and a N-acylurea.
